Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties
Nilufer P. Seth(Johnson & Johnson (United States)), Leona E. Ling(Johnson & Johnson (United States)), Julia Brown(University of Leeds), Lynn Markowitz(Johnson & Johnson (United States)), Traymon Beavers(Rutgers, The State University of New Jersey), Steven Tyler, Pushpa Narayanaswami(Unknown), Fiona Elwood(Novartis (Switzerland)), Siddharth Sukumaran(Johnson & Johnson (United States)), Matthew L. DuPrie(Johnson & Johnson (United States)), Viraj Parge(Johnson & Johnson (United States)), Jay Duffner(Johnson & Johnson (United States)), James W. Meador(Johnson & Johnson (United States)), Laura I. Rutitzky(Johnson & Johnson (United States)), Sayak Bhattacharya(Johnson & Johnson (United States)), Edward Cochran(Johnson & Johnson (United States)), Katie Abouzahr(Johnson & Johnson (United States)), Yang Wang(Johnson & Johnson (United States)), Rui Xu(China University of Geosciences), Amit Choudhury(Johnson & Johnson (United States)), Y.-H. Pao(Johnson & Johnson (United States)), Sujatha Kumar(Johnson & Johnson (United States)), Karen Price(Purchase College), Thomas M. Daly(Johnson & Johnson (United States)), Sucharita Roy(Johnson & Johnson (United States)), Hsin Chen(Johnson & Johnson (United States)), William Avery(Johnson & Johnson (United States)), Samuel Sihapong(Johnson & Johnson (United States)), Jonathan J. Hubbard(Brigham and Women's Hospital)
Cited by 33
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445